Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that the U.S. Food and Drug ...
Clinical Trials Arena on MSN
Revolution’s RAS inhibitor pipeline posts more pancreatic cancer trial wins
The biotech’s G12D-selective RAS blocker has demonstrated its first and second-line combinatory potential in pancreatic cancer.
NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, ...
At a pivotal moment for pancreatic cancer, Break Through Cancer and the Lustgarten Foundation today, with support from the Cinelli Family Foundation, announced a $16 million investment in the ...
University of Michigan Health experts said the drug represents the first major therapeutic advancement for treating the ...
This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. Former Senator Ben Sasse has become an unlikely public face of a drug that researchers are ...
Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced results from two Phase 1/2 ...
Adding immunotherapy to a new type of inhibitor that targets multiple forms of the cancer-causing gene mutation KRAS kept pancreatic cancer at bay in preclinical models for significantly longer than ...
PHILADELPHIA — The use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) is associated with a significant decrease in the risk for early-onset colorectal cancer (EO-CRC) in patients with type 2 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results